Results of sensitivity analyses
| Incremental effect | Incremental costs | ICER €/QALY | Dominance (%) | Probability cost-effective λ=€20.000 (%) | Probability cost-effective λ=€80.000 (%) | |
|---|---|---|---|---|---|---|
| Healthcare perspective | ||||||
| Breast (n=165) | 0.01 | 1861 | 432.644 | 5 | 8 | 17 |
| Colon (n=29) | 0.03 | −4743 | D* | 100 | 100 | 100 |
| Without radio and cancer therapy† | ||||||
| Breast (n=165) | 0.01 | 1638 | 200.134 | 2 | 4 | 16 |
| Colon (n=29) | 0.03 | −2393 | D* | 100 | 99 | 100 |
| Subgroup no immunotherapy | ||||||
| Breast (n=131) | 0.01 | 1759 | 299.495 | 4 | 6 | 17 |
| Maximum cost price PACT (150%) | ||||||
| Breast (n=165) | 0.01 | 3214 | 4399.548 | 1 | 2 | 6 |
| Colon (n=29) | 0.03 | −3930 | D* | 100 | 100 | 100 |
| Minimum cost price PACT (50%) | ||||||
| Breast (n=165) | 0.01 | 2560 | 261.030 | 4 | 6 | 13 |
| Colon (n=29) | 0.03 | −4638 | D* | 100 | 100 | 100 |
*D=ICER not provided because the intervention is considered dominant to usual care.
†Chemotherapy, immunotherapy, hormone therapy and required day care hospital admissions.
ICER, incremental cost-effectiveness ratio.